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A B S T R A C T
Cellular senescence was first described by Hayflick and Moorhead in the 1960s as the irreversible arrest of cells
following prolonged cultivation. Telomere shortening is the key mechanism driving replicative senescence in
human fibroblasts. Later, pioneering work by Olivier Toussaint and others showed that stress plays a major role
in the induction of senescence in vitro, a phenomenon known as stress-induced premature senescence or SIPS. It
is also now widely accepted that senescence plays a role in vivo. An emerging body of evidence from animal
models, and particularly mice, has demonstrated an important role for senescence in several processes such as
embryonic development, wound healing, tumour suppression and ageing. However, mostly due to a lack of
availability of tissues and specific markers, less is known about the importance of cell senescence in humans. In
this review, we summarize some of the key findings in the field of senescence, stress-induced senescence and
telomeres. We focus particularly on the role of telomere dysfunction and senescence during the ageing process as
well as potential interventions, including pharmacological approaches like telomerase activators and senolytics,
to counteract their detrimental effects in ageing and disease.
1. Introduction
Because cells are the fundamental building blocks of humans and
animals, it is clear that cellular changes contribute to the ageing pro-
cess. A major open question, however, is the nature of those changes
and how exactly they contribute to degeneration and disease in old age.
In 1961, Leonard Hayflick and Paul Moorhead discovered that human
cells can only divide a finite number of times in culture (Hayflick and
Moorhead, 1961). The limited proliferative ability of human cells in
vitro, known as replicative senescence (RS), has since become a major
focus of research in biogerontology. Hayflick and Moorhead worked
with fibroblasts, a cell type found in connective tissue, but RS has been
found in other cell types (de Magalhaes and Toussaint, 2004c): kera-
tinocytes, endothelial cells, lymphocytes, adrenocortical cells, vascular
smooth muscle cells, chondrocytes, etc. In addition, RS is observed in
cells derived from embryonic tissues, in cells from adults of all ages, and
in cells taken from many animals: mice, chickens, Galapagos tortoises,
etc. (Hayflick, 1994). The number of divisions cells undergo in culture
varies considerably between cell types and species.
In addition to RS, a number of factors can accelerate and/or trigger
cell senescence, including various forms of stress like oxidative stress.
Depending on the dose of stressor used, a cell population will react in
different ways. For instance, a high cytotoxic dosage will cause such an
amount of damage that cellular biochemical activities decrease leading
to cellular death by necrosis. The level of cumulative damage sustained
by cells determines whether programmed cell death–apoptosis–can
unfold or, if the damage is lower, senescence. Since a cellular popula-
tion is not homogeneous, the dosage of the stressor will shift the per-
centage of cells executing each of the possible programs depending on
the amount of stress, respectively, from no stress to high stress: cellular
proliferation, senescence, apoptosis, and necrosis (Toussaint et al.,
2002). Oncogenes such as ras can also induce senescence (Serrano et al.,
1997), though oncogene-induced senescence will not be discussed here
at length. The way sublethal stress can accelerate the appearance of the
senescent phenotype in cells has been deemed as another form of cel-
lular senescence, termed stress-induced premature senescence (SIPS)
(Brack et al., 2000). The work of Olivier Toussaint focused primarily on
senescence, and specifically replicative senescence and SIPS. Our aim
here is to review the potential impact of senescence and SIPS on the
ageing of whole organisms and humans in particular.
2. Of telomeres and senescence
During in vitro ageing, the telomeres shorten gradually in each sub-
cultivation (Harley et al., 1990). Telomere shortening is the primary
cause of RS in human fibroblasts, since it has been shown that ectopic
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expression of telomerase, an enzyme able to counteract telomere
shortening, is able to bypass the senescence-induced arrest (Bodnar
et al., 1998).
Telomeres are tandem TTAGGG repeats found at the ends of chro-
mosomes, associated with several telomere-binding proteins. With each
cell division telomeres shorten progressively, due to the so called “end-
replication problem”. This is due to the intrinsic inability of DNA
polymerases to replicate the telomere C-rich lagging-strand. During the
process of lagging-strand synthesis, RNA primers allow DNA poly-
merases to initiate DNA replication; however, upon removal of the last
primer from the 3′ end, the newly synthesized strand will inevitably be
a few nucleotides shorter (de Lange, 2005).
We now understand more clearly why the shortening of telomeres
results in senescence. Telomeres are thought to form a lariat-like
structure called telomere-loop (t-loop) which is stabilized by several
telomere binding proteins collectively known as the “shelterin” com-
plex (de Lange, 2005). It is thought that with each cell division, telo-
mere shortening precipitates the loss of “shelterin” components and the
destabilization of the t-loop conformation, resulting in exposure of the
telomere end (Griffith et al., 1999). Consistent with this hypothesis,
depletion of “shelterin” components such as TRF2 or POT1 leads to
activation of a DNA damage response (DDR) at telomere ends (Takai
et al., 2003; Wu et al., 2006). Moreover, it was shown that during RS,
fibroblasts accumulate proteins involved in the DDR at telomeric re-
gions, including γH2A.X, 53BP1, MDC1 and NBS1 (d'Adda di Fagagna
et al., 2003). DDR activation can result in the activation of transcription
factor p53 which is involved in a variety of processes including DNA
repair and apoptosis, but most notably results in expression of cyclin-
dependent kinase inhibitor p21, which together with activation of p16,
are thought to be the major pathways in the induction of senescence
(Beauséjour et al., 2003).
3. Is SIPS telomere-independent?
Traditionally, SIPS was thought to be distinct from RS due to the
lack of involvement of telomere shortening (Parrinello et al., 2003).
Exposure to different types of acute sub-lethal stresses such as oxidative
stress and DNA damaging agents was shown to induce cellular senes-
cence in different cell types at relatively short periods of time (ranging
from 3 to 10 days) without or with modest telomere shortening. This
led to the widespread idea that telomeres were not involved in this
process, since considerable cell division would be required for telo-
meres to shorten until reaching a critical length. Moreover, mouse-de-
rived embryonic fibroblasts, which have long telomeres and express the
enzyme telomerase, were shown to undergo SIPS (Parrinello et al.,
2003). Work by Olivier Toussaint also showed that telomerase expres-
sion in normal human fibroblasts does not protect against SIPS, sug-
gesting that mechanisms other than telomere shortening must cause the
appearance of the senescence phenotype (de Magalhães et al., 2002).
SIPS was then suggested to be mediated by oxidative DNA damage and
occurring independently of telomeres.
However, recent data has challenged the concept that SIPS is a
telomere-independent process. Induction of SIPS is characterized in-
itially by DNA damage, which occurs randomly all over the genome,
and subsequent activation of a DDR. As the senescent phenotype de-
velops, most of the DNA damage is repaired within 24 h; however,
damage at telomeric regions remains unrepaired for months, con-
tributing to a persistent and unresolved DNA damage response (Hewitt
et al., 2012). Interestingly, these telomeric lesions occur irrespectively
of telomere length and the presence or absence of the enzyme telo-
merase (Fumagalli et al., 2012; Hewitt et al., 2012). Thus, while SIPS
induced by sub-lethal acute stress is not driven by the shortening of
telomeres per se, in some circumstances SIPS can still be classified as a
telomere-dependent process.
Mechanistically, there is a reason why telomeric regions differ from
the rest of the genome in terms of repair. Telomere-binding proteins
such as TRF2 have been shown to play a role in the inhibition of non-
homologous end joining as a way to prevent telomere end-to-end fu-
sions, precursors of genomic instability in cells. Similarly, when cells
are exposed to oxidative or DNA damaging agents, if damage is induced
in telomeric regions, TRF2 inhibits repair and contributes to an un-
resolved DDR which helps stabilize the senescence arrest (Fumagalli
et al., 2012).
Damage at telomeric regions is not exclusive to cells in vitro. Normal
mice show an age-dependent increase in telomeric-associated DNA
damage foci (TAF) in the gut, liver and lung of mice, which occurs
independently of telomere length (Birch et al., 2015; Hewitt et al.,
2012). Telomere damage irrespectively of length has also been ob-
served with age in hippocampal neurons and in the liver of baboons
(Fumagalli et al., 2012). Moreover, analysis of individual telomeres in
small airway epithelial cells in the lungs of Chronic Obstructive Pul-
monary Disease (COPD) patients, which show increased senescence
markers such as p16, has also revealed that damaged telomeres are not
significantly shorter (Birch et al., 2015).
Telomere-length independent senescence was also observed in the
context of oncogene-induced senescence. In melanocytic nevi it was
shown that telomeres signalling a DDR were not shorter when com-
pared to functional ones (Suram et al., 2012). Interestingly, studies
have suggested that having long telomeres may in fact be dis-
advantageous. In a study where telomeres were elongated in human
cancer cells, it was shown that cells with very long telomeres were more
sensitive to ionising irradiation (Fairlie and Harrington, 2015).
4. The role of telomere-induced senescence in vivo
In vivo, telomere length is heterogeneous (Serra and von Zglinicki,
2002; Takubo et al., 2002). Telomere shortening in vivo has been re-
ported (de Magalhaes and Toussaint, 2004c), for example in liver cells
(Aikata et al., 2000), lymphocytes (Pan et al., 1997), skin cells (Lindsey
et al., 1991), blood (Iwama et al., 1998), and colon mucosa (Hastie
et al., 1990). For instance, telomere shortening appears to impact on the
function of immune T cells, and telomerase activators can restore a
more youthful functional profile (Effros, 2009). Weak correlations be-
tween telomere length and donor age have been reported (Allsopp
et al., 1992; Kammori et al., 2002; Njajou et al., 2007), though some
studies found no correlation at all (Mondello et al., 1999; Nwosu et al.,
2005; Renault et al., 2002; Serra and von Zglinicki, 2002; Takubo et al.,
2002). Overall, telomere shortening may occur in some tissues in vivo in
association with certain pathologies and with age. An association be-
tween telomere length and mortality has been reported in people aged
60 and over (Cawthon et al., 2003), and telomere shortening appears to
be accelerated in people living more stressful lives (Epel et al., 2004).
While these results support the idea that telomere shortening is a
marker of stress and age-related pathology, they do not prove that
telomere shortening is a causal factor in ageing.
Probably, the best evidence for a causal role of telomeres in the
ageing process derives from data from telomerase-deficient mice. Mice
carrying a homozygous deletion of the RNA component of telomerase
(mTERC) only experience accelerated age-related degeneration after
being bred for several generations, which results in telomere shortening
(Blasco et al., 1997). This in turn results in critically short telomeres
which are responsible for an early onset of senescence and apoptosis
(Lee et al., 1998) and reduced regenerative capacity of proliferative
tissues such as the intestine and the hematopoietic system (Wong et al.,
2003). Interestingly, deletion of p21 in these mice improves re-
generative capacity of the intestine and hematopoietic stem cells
(Choudhury et al., 2007). Reintroduction of telomerase in telomerase-
deficient mice is able to revert the premature ageing phenotype ob-
served in various tissues (Jaskelioff et al., 2011).
In terms of comparative biology, no connection appears to exist
between the mean telomere length of cells and the longevity of mam-
malian species. Although humans are the longest-lived primate, they
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have the shortest telomeres (Kakuo et al., 1999; Steinert et al., 2002).
Mice have massively long telomeres and feature high telomerase ac-
tivity in many organs, in contrast to humans (Prowse and Greider,
1995). Interestingly, inbred mice have long (Kipling and Cooke, 1990)
while wild mice have short telomeres (Hemann and Greider, 2000). In
rodents, telomerase activity correlates negatively with lifespan but does
not correlate with longevity (Seluanov et al., 2007). The largest com-
parative study of telomeres and telomerase, involving over 60 mam-
malian species, found that smaller, short-lived species tend to have long
telomeres and high levels of telomerase (Gomes et al., 2011). Taken
together, it seems that the evolution of large body sizes and longevity is
strongly associated with the evolution of short telomeres and telo-
merase suppression, presumably for tumour suppression (de Magalhaes,
2013; Gomes et al., 2011).
Altogether, these studies suggest that: 1) telomere length is not a
limiting factor in an organism’s lifespan, and 2) if senescence plays a
detrimental role during ageing in vivo (discussed in the next section),
this may occur independently of telomere length.
5. Do senescent cells accumulate with age in tissues?
For a long time it was debated whether the discovery made by
Hayflick and Moorhead had any physiological relevance or was merely
an artefact of cells grown in relatively artificial culture conditions.
Hayflick and Moorhead proposed that senescence may represent
ageing, however, recent data has revealed that this view is too sim-
plistic, since senescence has been shown to play multiple important
physiological roles, such as: tumour suppression (Serrano et al., 1997),
tissue repair and wound healing (Demaria et al., 2014; Krizhanovsky
et al., 2008), embryonic development (Muñoz-Espín et al., 2013; Storer
et al., 2013) and age-related degeneration (Baker et al., 2011). Senes-
cent cells also appear to have benefits in promoting insulin secretion by
pancreatic beta cells (Helman et al., 2016). In addition, senescent cells
have been detected in the context of many different age-related dis-
eases, including atherosclerosis, lung disease, diabetes and many others
(Munoz-Espin and Serrano, 2014).
Given the multitude of functions of senescent cells, which can be of
a positive or negative nature depending on the context, it has been
argued that there may be different types of senescence rather than a
universal phenotype. For instance, senescence during embryonic de-
velopment occurs transiently, since senescent cells are rapidly removed
by the immune system after executing their role, and is not associated
with the activation of a DDR (Muñoz-Espín et al., 2013). In contrast,
during ageing, senescent cells are thought to be persistent, induced by
random molecular damage and associated with the activation of a DDR
(Munoz-Espin and Serrano, 2014). Recent work has demonstrated that
senescent cells are able to attract (potentially via the secretion of che-
mokines) different immune cells, including Natural Killer cells, mac-
rophages and T-lymphocytes which are involved in their specific
clearance from tissues (Kang et al., 2011; Krizhanovsky et al., 2008; Xue
et al., 2007). It is possible that persistence of senescent cells in tissues
during ageing and age-related diseases is a consequence of the inability
of the immune system to clear senescent cells – in view of the well
reported decline of the immune system with age – however this has not
yet been experimentally tested.
Do senescent cells accumulate with age? One of the main challenges
to the study of senescence in vivo has been the absence of a universal
marker that can unequivocally identify senescent cells. The most
widely-used marker is the presence of senescence-associated β-ga-
lactosidase (SA-β-gal) activity. The enzyme β-galactosidase, a lyso-
somal hydrolase, is normally active at pH 4, but in senescent cells it
often happens for β-galactosidase to be active at pH 6, a shift that can
be detected with a simple biochemical assay. Both in vitro and in vivo,
the percentage of cells positive for SA β-gal increases with, respectively,
population doublings and age (Dimri et al., 1995). However, there are
major limitations to the use of this marker, since SA-β-Gal staining can
also be detected in immortalized cells and quiescent cells induced by
both confluency and serum starvation (Cristofalo, 2005). Also, it has
been suggested that a major limitation of using SA β-gal staining in vivo
is a false-positive signal from macrophages and other pro-inflammatory
cells (Hall et al., 2016). In addition, since it requires fresh tissues, its
detection is not straightforward technically and has more than often
generated conflicting results.
Given the challenge of identifying a specific marker able to identify
senescent cells, most researchers currently rely on a multiple marker
approach. Indeed, several markers have been identified which are
closely associated with cellular senescence, including absence of pro-
liferation markers (Lawless et al., 2010), changes in heterochromatin
(Narita et al., 2003), telomere-associated DNA damage (Hewitt et al.,
2012), expression of cyclin-dependent kinase inhibitors p21, p16
(Baker et al., 2016), and senescence-associated distension of satellites
(Swanson et al., 2013). In a variety of mouse tissues, it is clear that most
of these markers increase with age; however, given the fact that most of
these markers are not exclusive for senescent cells, the exact frequency
of senescent cells in older tissues is still unknown. Furthermore, given
the limited availability of tissues, little is known about the accumula-
tion of senescent cells with age in healthy humans.
Interestingly, many senescence markers have also been found in
post-mitotic tissues such as neurons (Jurk et al., 2012), adipocytes
(Baker et al., 2011; Minamino et al., 2009) and osteocytes (Farr et al.,
2016), which goes against the dogma that senescence is restricted to
proliferating cells. It is possible that with ageing, senescence-inducing
pathways (which play roles in tumour suppression and during devel-
opment) can be inadvertently switched on during ageing of post-mitotic
cells. However, given that the primary characteristic of senescence is a
permanent cell-cycle arrest, the consequences of the activation of these
pathways in post-mitotic cells are still not understood.
6. Senescent cells can cause tissue disruption and/or degeneration
Apart from cell-cycle arrest, senescent cells have been shown to
experience dramatic changes in terms of gene expression, metabolism,
epigenome and, importantly, have a distinct secretome profile, known
as the Senescence-Associated Secretory Phenotype (SASP) (Coppé et al.,
2008). The SASP includes pro-inflammatory cytokines as well as che-
mokines, growth factors and extracellular matrix-degrading proteins
which may impact on the tissue microenvironment. Indeed, work by
Olivier Toussaint revealed overexpression of cytokines (e.g., IL6) and
matrix metalloproteinase in late passage fibroblasts (de Magalhaes
et al., 2004). The SASP is thought to have evolved as a way for senes-
cent cells to communicate with the immune system (potentially to fa-
cilitate their own clearance), but also as an extracellular signal to
promote the regeneration of tissues through the stimulation of nearby
progenitor cells.
It has been shown that a “chronic” SASP is able to induce senescence
in adjacent young cells, contributing to tissue dysfunction (Acosta et al.,
2013; Jurk et al., 2014) and paradoxically tumorigenesis (Krtolica
et al., 2001). Repeated stimulation of WI-38 human fibroblasts with
pro-inflammatory cytokines interleukin-1 α (IL-1α) or tumour necrosis
factor-α (TNF-α) induces SIPS (Dumont et al., 2000). These cytokines'
circulating levels increase in vivo (Lio et al., 2003), favouring in-
flammation and perhaps contributing to SIPS in vivo; senescent cells
might then also contribute to increase inflammatory levels, creating a
positive feedback loop (Fig. 1). Senescent cells also show mitochondrial
dysfunction and increased production of Reactive Oxygen Species
(ROS) (Passos et al., 2010, 2007). ROS-derived from senescent cells
have also been shown to induce DNA damage in neighbouring pro-
liferating cells (Nelson et al., 2012). Because senescent cells can secrete
pro-inflammatory cytokines and other factors that disrupt the tissue
microenvironment, they may contribute to disruption of cell and tissue
function. Even a small percentage of senescent cells, in fact, may in-
terfere with tissue homeostasis and function (Shay and Wright, 2000).
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Studies using genetically-modified mice found that genetic clear-
ance of senescent cells delays ageing-associated disorders in old mice
(Baker et al., 2016, 2011; Xu et al., 2015). Initially this was observed in
progeroid mice that accumulate more senescent cells than normally
(Baker et al., 2011). Clearance of senescent cells also did not extend
lifespan in progeroid mice, which Baker et al. claim is due to their mice
dying primarily of heart disease that is not affected by the treatment.
More recently, using the same genetic approach, the same group found
that removing senescent cells in normal mice preserves health in some
tissues, though not in others, protects from cancer and extends median
(but not maximum) lifespan (Baker et al., 2016). Other studies have
shown beneficial effects of genetic clearance of senescent cells: Elim-
ination of p16 positive cells was shown to enhance adipogenesis and
improve metabolic function in old mice (Xu et al., 2015), and clearance
of naturally occurring p19Arf-positive cells restored lung compliance,
structure, and elasticity in aged mice (Hashimoto et al., 2016). There-
fore, these landmark studies provide evidence that senescent cells can
promote age-related phenotypes, at least in a subset of organs.
7. Genetics of ageing and links to senescence
As mentioned above, senescent cells likely accumulate in some tis-
sues and may contribute to organ dysfunction, yet whether they are
causal factors in ageing remains a subject of debate. Some genetic in-
terventions that alter mammalian ageing appear to influence tissue
homeostasis by affecting senescence, cell proliferation, and cell death,
yet such evidence is circumstantial (de Magalhaes and Faragher, 2008).
Evidence from genetic manipulation experiments of players involved in
telomeric signal transduction is mixed (de Magalhaes, 2004). Increasing
the dosage in mice of INK4a/ARF (the gene coding the mouse homolog
of p16) offers resistance against cancer but does not affect ageing
(Matheu et al., 2004). Another study found that INK4a/ARF induction
in mice results in premature senescence and inhibits cell proliferation
but does not induce cell senescence (Boquoi et al., 2015). There is also
evidence that p53 may influence ageing in mice (Donehower, 2002),
but it is not clear the same is true for humans. Likewise, disruption of
p63, a homologue of p53, appears to accelerate ageing in mice (Keyes
et al., 2005), yet human defects in p63 do not (Celli et al., 1999). Mouse
strains with increased levels of p53 and INK4a/ARF are long-lived
(Matheu et al., 2007), though it is unclear whether their ageing process
is altered. Arguably the strongest evidence for a role of telomerase in
ageing comes from telomerase-overexpressing mice also engineered to
resist cancer via enhanced expression of p53 and INK4a/ARF, as these
mice are long-lived (Tomas-Loba et al., 2008). Even though it is not
clear whether ageing is delayed in these animals or the exact me-
chanisms, these findings point towards some level of protection from
age-related degeneration via optimization of pathways associated with
telomeres and RS. Telomerase gene therapy in old mice also modestly
increased lifespan (Bernardes de Jesus et al., 2012). It should be noted,
however, that telomerase may have functions independent of telomere
elongation, such as in protecting mitochondria from stress (Ahmed
et al., 2008). As abovementioned, another study showed that telo-
merase reactivation reverses degeneration in mice (Jaskelioff et al.,
2011). However, this study was conducted in animals that have no
Fig. 1. During the ageing process, exposure to intrinsic and extrinsic stresses can lead to the accumulation of senescent cells. Senescent cells in tissues (if not cleared by the immune
system) produce a SASP which can, over time, induce senescence in neighbouring young cells, resulting in further accumulation of senescent cells. Senescent cells contribute to tissue
dysfunction via induction of the SASP. Therapeutically, two main approaches are currently being tested to counteract the detrimental effects of senescence during ageing: 1) drugs which
suppress the SASP- this approach allows senescent cells to remain in tissues but aims to prevent its associated bystander effects; 2) drugs that specifically kill senescent cells, named
“senolytics”.
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telomerase to begin with and thus develop a number of pathologies.
Benefits from reactivating telomerase in mice that become sick for lack
of telomerase are hardly surprising.
Olivier Toussaint was also involved in establishing databases of
ageing-related genes (de Magalhaes et al., 2005) and in developing
bioinformatics methods for studying ageing (de Magalhaes and
Toussaint, 2004b). Of note, we performed the first systematic analysis
of ageing-related genes (de Magalhaes and Toussaint, 2004a). More
recently a new database of genes associated with cell senescence, en-
titled CellAge (http://genomics.senescence.info/cells/), has been de-
veloped to facilitate system-level analysis of cell senescence. Further-
more, a gene expression meta-analysis across mammalian tissues and
species found signatures of senescent cells in aged tissues (de Magalhaes
et al., 2009). In humans, one study measured changes in telomere
length in over 4000 people over 10 years but found no association with
mortality or morbidity (Weischer et al., 2014). However, human epi-
demiological data suggest a causal role of both short and very long
telomeres in cancer, heart disease and other age-related diseases (Codd
et al., 2013), so some impact of telomere shortening in age-related
diseases besides cancer cannot be excluded.
8. Pharmacological prospects by targeting senescence
Some have argued that if telomerase can avoid ageing in cells in
vitro, maybe it can be used to combat human ageing (Fossel, 1996). A
number of companies and labs are developing telomerase-based
therapies to fight ageing and at least one product, a natural product-
derived telomerase activator called TA-65, is already available. One
study reported that taking TA-65 may result in the decline of senescent
immune system cells in patients (Harley et al., 2011). TA-65 can also
increase telomerase levels in some mouse tissues and was reported to
improve health indicators in mice but it did not increase mean or
maximum lifespan (de Jesus et al., 2011).
Even though our knowledge of telomerase is still imperfect, it is
questionable whether telomerase-activating therapies will succeed in
retarding human ageing (de Magalhaes and Toussaint, 2004c). Firstly,
mice expressing lots of telomerase do not live longer (Artandi et al.,
2002). Moreover, telomerase is important in cellular proliferation, yet
many of our organs, such as the brain, are mostly composed of cells that
do not proliferate. Hence, telomerase will do little to alleviate ageing in
these tissues. Lastly, there is ample evidence that telomerase favours
tumorigenesis and so telomerase-based therapies may foster cancer
development. Although research on telomerase is still in its infancy,
there are questions about the efficiency and long-term safety of telo-
merase-based anti-ageing therapies. The fact that TA-65 can increase
telomerase levels but does not extend lifespan in mice (de Jesus et al.,
2011) is in line with this reasoning.
Some companies are also selling telomere measurements to estimate
biological age. Although telomere shortening may be a marker of cer-
tain diseases, there is no evidence at present that telomere length is a
better indicator of biological age than chronological age.
Another strategy which has proven promising is the use of drugs
that can specifically eliminate senescent cells and are commonly called
“senolytics” (Fig. 1). Several drugs have been shown to eliminate se-
nescent cells in vivo and have beneficial effects in models of ageing and
age-related disease. Dasatinib and quercetin (D + Q) when given in
combination have been shown to reduce senescent cells in aged, ra-
diation-exposed and progeroid mice, improving several healthspan
parameters (Zhu et al., 2015). Moreover, D + Q administration was
shown to improve vasomotor function in aged and hypercholester-
olaemic mice (Roos et al., 2016), improve lung function in a mouse
model of idiopathic pulmonary fibrosis (Schafer et al., 2017) and in
mouse models of hepatic steatosis (Ogrodnik et al., 2017). Inhibitors of
the BCL-2 family, such as ABT-263 (navitoclax) and ABT-737, have
been shown to reduce senescent hematopoietic and muscle stem cells in
radiation-exposed and aged mice (Chang et al., 2016) and senescent
cells in the lung and epidermis (Yosef et al., 2016). Further highlighting
the potential of targeting senescence as a way to counteract age-related
diseases, recent work in mice has shown that genetic elimination of
p16-positive senescent cells ameliorated atherosclerosis (Childs et al.,
2016) and osteoarthritis (Jeon et al., 2017). While these strategies have
been shown to have beneficial effects during mouse ageing in vivo, it is
still unclear what are the effects of these therapies on young tissues, as
discussed in (Birch and Passos, 2017). Recently, a FOXO4 peptide that
perturbs the FOXO4 interaction with p53 was shown to clear senescent
cells and improve healthspan in aged and progeroid mice (Baar et al.,
2017).
Finally, since the SASP has been proposed to be an inducer of tissue
dysfunction during ageing, another potential strategy to counteract the
negative effects of senescent cells is to identify SASP-suppressing drugs.
While it is still unclear whether the SASP specifically contributes to
ageing, several studies suggest that its inhibition can improve lifespan
and healthspan. For instance, inhibition of the mTOR pathway (using
the drug rapamycin), which has been shown to extend lifespan in a
variety of model organisms (de Magalhaes et al., 2012; Harrison et al.,
2009), is an effective SASP suppressor (Correia-Melo et al., 2016;
Herranz et al., 2015; Laberge et al., 2015). Inhibition of the JAK
pathway (using the drug ruxolitinib) has been shown to suppress the
SASP and alleviate age-related tissue dysfunction (Xu et al., 2015).
Inhibition of NF-κB signalling (the main transcription factor regulating
the SASP) both genetically and pharmacologically, has been shown to
prevent age-related deterioration in progeroid mouse models (Osorio
et al., 2012). However, given the fact that the SASP is required in
certain physiological contexts, it is still unclear whether targeting the
SASP would be a viable anti-ageing therapy.
9. Concluding remarks
While there is little evidence to suggest that cells running out of
divisions are a major factor in ageing, it is possible that stress and
various insults are contributors to senescence in vivo. Even a small
fraction of senescent cells in organs may impair tissue renewal and
homeostasis, decrease organ function, and contribute to the ageing
phenotype, as shown by the studies genetically ablating senescent cells.
While our knowledge about senescence in vivo has increased ex-
ponentially in the last decade, this is mostly through work using la-
boratory mice, which have known limitations (de Magalhaes, 2014). As
such, one major challenge in the field is to determine levels of senescent
cells in human tissues and whether they contribute to ageing and/or
pathologies in humans. Furthermore, given the diverse functions of
senescent cells in processes such as repair, wound healing, cancer, de-
velopment and ageing, we still need to better characterize senescence in
vivo in these different contexts. Finally, we still know very little about in
vivo rates of occurrence and turnover of senescent cells. Therefore, in
spite of recent advances in our understanding of senescence, telomeres
and SIPS, many questions remain and these will be timely and im-
portant areas of research for years to come.
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